-transparent.png){kind=logo}
Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4-directed antibody-drug conjugate.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
August 2020,
The AAPS journal,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
June 2015,
Molecular pharmaceutics,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
March 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
January 1998,
Nursing standard (Royal College of Nursing (Great Britain) : 1987),
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
January 1987,
Annals of the New York Academy of Sciences,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
February 2023,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
January 1978,
The Central African journal of medicine,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
September 1977,
The Central African journal of medicine,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
March 2022,
Signal transduction and targeted therapy,
Ana Carolina Veneziani, and
Suku Sneha, and
Amit M Oza
January 2022,
Exploration of targeted anti-tumor therapy,
